Iovance Biotherapeutics (IOVA) Competitors

Vaxcyte (NASDAQ:PCVX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership.

Which has higher earnings and valuation, PCVX or IOVA?

Vaxcyte has higher earnings, but lower revenue than Iovance Biotherapeutics. Vaxcyte is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$402.27M	-$3.80	-9.43
Iovance Biotherapeutics	$164.07M	7.17	-$444.04M	-$1.30	-2.76

Does the media refer more to PCVX or IOVA?

In the previous week, Vaxcyte had 10 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 16 mentions for Vaxcyte and 6 mentions for Iovance Biotherapeutics. Vaxcyte's average media sentiment score of 1.41 beat Iovance Biotherapeutics' score of 1.07 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	10 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in PCVX or IOVA?

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 12.1% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts rate PCVX or IOVA?

Vaxcyte presently has a consensus price target of $136.50, suggesting a potential upside of 280.86%. Iovance Biotherapeutics has a consensus price target of $18.22, suggesting a potential upside of 407.58%. Given Iovance Biotherapeutics' higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10
Iovance Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Does the MarketBeat Community prefer PCVX or IOVA?

Iovance Biotherapeutics received 517 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 74.48% of users gave Iovance Biotherapeutics an outperform vote.

Company	Underperform	Outperform
Vaxcyte	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%
Iovance Biotherapeutics	Outperform Votes 572 74.48%	Underperform Votes 196 25.52%

Which has more volatility & risk, PCVX or IOVA?

Vaxcyte has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Is PCVX or IOVA more profitable?

Vaxcyte has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -451.25%. Vaxcyte's return on equity of -23.53% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-23.53%	-22.20%
Iovance Biotherapeutics	-451.25%	-58.43%	-45.48%

Summary

Vaxcyte beats Iovance Biotherapeutics on 12 of the 18 factors compared between the two stocks.